-
- Published: April 28, 2023 11:11
New Delhi: As an increasing number of overweight Americans seek medications such as Ozempic and Wegovy which marketed by celebrities and on social media to help them lose weight. However, an even more potent obesity pill is ready to disrupt therapy. Tirzepatide, an Eli Lilly & Co. medicine licensed for the treatment of type 2 diabetes under the brand – Mounjaro, helped persons with the illness who were overweight or obese lose as much as sixteen percent of their body weight or more than 34 pounds, the firm said on Thursday.
According to an organization’s press release, it also assisted patients in lowering their blood sugar levels. The findings have yet to be peer-reviewed or accepted for publication in a medical journal.
Dr. Nadia Ahmad, an associate vice president at Eli Lilly and the firm’s medical director of obesity clinical research, said the company was delighted with the results, especially given how difficult it is for individuals with type 2 diabetes to lose weight.
Tirzepatide is now marketed as Mounjaro and is approved to assist persons with type 2 diabetes in controlling their blood sugar levels.
In order to make tirzepatide a direct rival to the most popular obesity medication Wegovy, Lilly claims it will use the results of the most recent research and findings from a prior study on weight loss in people without type 2 diabetes to request that the US Food and Drug Administration expedite the approval of the drug for weight loss.
Tirzepatide mimics the activity of two distinct gut hormones. When blood sugar levels rise after eating, the medication encourages the body to create more insulin, lowering blood sugar levels. It also delays the passage of food from the stomach, allowing people to feel fuller for extended periods of time. In clinical studies, persons who received tirzepatide suffered greater nausea, vomiting, and diarrhoea than those who received a placebo injection.
It appears to help patients lose significant amounts of weight, as do other medications in its class. If those results stand up in reality, it will be the most powerful injectable weight loss medicine.
Indeed, Lilly plans to start a research this week that will set Mounjaro against Wegovy in a head-to-head battle with 700 participants over 61 sites in the United States and Canada. The research will be completed in February 2025.
